Public-Private Partnerships Like IMI Crucial to Industry's Future, Argue Leaders
Executive Summary
Public-private partnerships like Europe's Innovative Medicines Initiative, the EU’s mechanism that promotes new treatment R&D, are crucial to the industry's future, according to Paul Stoffels, Chairman global R&D pharmaceuticals at Johnson & Johnson.
You may also be interested in...
EFPIA Urges Drug Makers To See Value In Mobile Apps
The head of EFPIA believes drug makers are squandering opportunities offered by mobile health applications, a key point in the European trade body’s new manifesto.
Firms May Lose Data Exclusivity Earlier Under Planned EU Adaptive Licensing Regime
Adaptive licensing is coming to Europe and, while it will be beneficial to patients, data exclusivity considerations may render it a double-edged sword to the innovative drug industry.
EFPIA Calls For Increased EU Collaboration Ahead Of European Elections
EFPIA’s call for more integration in approaches to some areas of health care ahead of the European Parliamentary elections in May could benefit research.